[HTML][HTML] Human anti-tumor immunity: insights from immunotherapy clinical trials

JG Egen, W Ouyang, LC Wu - Immunity, 2020 - cell.com
Therapeutics that target the T cell inhibitory checkpoint proteins CTLA-4 and PD (L) 1 are
efficacious across a broad range of cancers, resulting in reductions in tumor burden and …

Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials.

JG Egen, W Ouyang, LC Wu - Immunity, 2020 - europepmc.org
Therapeutics that target the T cell inhibitory checkpoint proteins CTLA-4 and PD (L) 1 are
efficacious across a broad range of cancers, resulting in reductions in tumor burden and …

Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials

JG Egen, W Ouyang, LC Wu - Immunity, 2020 - pubmed.ncbi.nlm.nih.gov
Therapeutics that target the T cell inhibitory checkpoint proteins CTLA-4 and PD (L) 1 are
efficacious across a broad range of cancers, resulting in reductions in tumor burden and …

[HTML][HTML] Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials

JG Egen, W Ouyang, LC Wu - Immunity, 2020 - Elsevier
Therapeutics that target the T cell inhibitory checkpoint proteins CTLA-4 and PD (L) 1 are
efficacious across a broad range of cancers, resulting in reductions in tumor burden and …

Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials

JG Egen, W Ouyang, LC Wu - paper.sciencenet.cn
Therapeutics that target the T cell inhibitory checkpoint proteins CTLA-4 and PD (L) 1 are
efficacious across a broad range of cancers, resulting in reductions in tumor burden and …

[引用][C] Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials

JG Egen, W Ouyang, LC Wu - Immunity, 2020 - cir.nii.ac.jp